Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response

Conclusions/Summary Temozolomide is an increasingly described treatment option for refractory pituitary adenomas and carcinomas. In the current report, we document rapid biochemical response following retreatment with temozolomide in aggressive pituitary adenoma. When "off label" salvage therapy with temozolomide is offered for patients with recurrent prolactinomas, retreatment at the time of recurrence can be considered.
Source: Journal of Oncology Pharmacy Practice - Category: Cancer & Oncology Authors: Tags: Case Reports Source Type: research